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Abstract: 
Australia was one of the first countries to introduce a publicly funded HPV 
vaccine program, and its introduction coincided with a media campaign to 
promote regular cervical screening. One issue with HPV vaccination is how 
it impacts on demand for screening. This study examines changes in women’s 
screening preferences following these two interventions, using a novel 
approach to policy evaluation based on repeated discrete choice experiments. 
The study extends our previous analysis of attitudes to screening by taking 
advantage of the timing of the choice experiments to examine the impact of the 
two policy changes on determinants of screening. We find that, unexpectedly, 
willingness to screen is generally lower post-interventions. The reason for this 
trend appears to be related to HPV vaccination. We also find that interventions 
have minor impacts on how women value screening attributes. Our approach 
allows us to examine the impact of provider behaviour. A simulation 
demonstrates that under certain conditions, participation rates can be increased 
by 40% to 50% if health providers actively encourage women to undertake a 
cervical screening test. 
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1. Introduction  
Cervical cancer is one of the most preventable forms of cancer, but remains 
the second most common women’s cancer worldwide (Parkin, 2005). In 
Australia, about 735 women are diagnosed with the cancer every year, and it 
is predicted that 1 in 150 women will develop the cancer by the age of 75. 
These numbers would be substantially lower if all women engaged in 
preventive behaviours. Cytology tests are available to detect pre-cancerous 
lesions, and under Medicare, the standard Pap test is free to Australian 
women. It is estimated that through regular screening, 90% of cervical cancer 
cases can be prevented. Despite this, there is evidence that Australian women 
are under-screened (Fernbach, 2001). Lack of awareness about cervical 
cancer and screening programs, and misunderstanding among women about 
their eligibility for these programs are among the leading reasons for this 
trend, suggesting that raising awareness is a necessary step towards successful 
cervical cancer prevention (Belkar et al. 2006; Mullins et al., 2008; Fernbach, 
2001; Marshall et al., 2007).  
 
The most recent cervical screening awareness campaign at a national level in 
Australia was launched in 2007. The campaign was led by a television 
advertisement aired through national networks prompting women to make a 
screening appointment if their last Pap test was more than two years ago. The 
experiences of previous health-oriented campaigns in general suggest that 
televised messages are a powerful means of influencing the behaviour of their 




Unlike other forms of cancer, the cause of cervical cancer is known: infection 
through the Human Papilloma virus (HPV). Preventing HPV infection with 
through vaccination is therefore a potentially effective strategy for preventing 
cervical cancer. In April 2007, the Australian government implemented an 
HPV vaccination program, one of the first national programs to be launched 
worldwide. The vaccination program provided HPV vaccines free to females 
aged 12 – 26 years old, through a school based program for girls 12-18 and 
through a “catch up program” delivered by primary care providers for women 
aged 18-26 . The public was informed about the availability of the vaccine 
through articles, banners, posters and pamphlets, but, unlike the screening 
promotion campaign, the introduction of the national vaccination program 
was not advertised on television.  
 
The aim of this study is to examine women’s screening preferences in 
response to these two interventions: the screening promotion and the 
vaccination program. The approach taken extends a policy evaluation to 
include analysis of the effects of the interventions on the determinants of 
screening. Specifically, discrete choice experiments (DCEs), a form of stated 
preference (SP) technique, are used to elicit women’s screening preferences 
as well as their valuations of various screening factors. SP data have become 
increasingly popular in health economic studies, providing behavioural data 
which are not available from revealed preference (RP) data sources (e.g., 
market survey) (Fiebig et al., 2009; Salkeld et al., 2000; Scott and Vick, 1998; 
Ryan et al., 2006; Costa-Font and Rovira, 2005; Dolan and Tsuchiya, 2011). 
By analysing the effects of the interventions on the screening determinants, in 
addition to their impact on choices, policymakers can make informed use of 
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these factors to shape future screening behaviour. For example, Gerard et al. 
(2003) use SP data to analyse determinants of breast screening participation 
and find that, while attributes of the screening are important, women’s 
participation decisions are also affected by factors such as the manner in 
which they were informed about screening and the screening environment 
offered by the health provider which can be policy targets.  
 
In our study, the identification of the effects of the interventions will be 
achieved through comparisons of outcomes of the ‘treated’ and ‘control’ 
groups, in the standard sense that only the former was exposed to any 
intervention. The availability of an identical DCE conducted in 2004, before 
both interventions were introduced (DCE1), provides one control group, 
allowing us to compare the preferences before and after the policy 
interventions. In addition, several other control groups are formed through 
spatial variations and randomisation in the follow-up DCE collected after 
both interventions (DCE2). These extra comparison groups are useful to 
isolate out any common (time) trend effect.  
 
The existing literature predicts that awareness would increase women’s 
willingness to be screened (Fernbach, 2001; Marcus and Crane, 1998; Jenkins 
et al., 1999; Mullins et al., 2008). A previous screening promotion campaign 
in New South Wales, for instance, recorded a 30% increase in screening 
uptake within 4 months of the promotion campaign (Shelley et al., 1991). 
However, never before has a screening promotion campaign been 
implemented at the same time as a vaccination program, another means to 
prevent cervical cancer. It could be hypothesised that the two interventions 
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could support one another, but alternatively, the vaccination program could 
also counteract the effectiveness of the screening campaign, for example due 
to misconceptions that vaccination can substitute for screening (Newall et al. 
2007; Kulasingam and Myers, 2003). This study will provide the first results 
in relation to these issues. 
 
2. Background 
Cervical cancer is a cancer of the cervix. The cancer develops when women 
are infected with high-risk strains of HPV (13-18 strains) for a number of 
years. As the progression of the cancer to an invasive state is slow (up to 10 
years) and pre-invasive stages are largely asymptomatic, regular screening is 
crucial. Early detection of abnormal cells is known to have high curative 
rates. In Australia, the current recommendation is for women to begin 
screening between the age of 18 and 21, or a year after commencing sexual 
activity, whichever is later, and continue two yearly screening until the age of 
70.  
 
For the past 40 years, the Pap test has been the main means of cervical 
screening, but recently alternative tests have been developed, most recently a 
HPV test to detect specifically high-risk strains of HPV. When used in 
conjunction with a Pap test, this test is almost 100% accurate. A Pap test 
alone is typically about 50-85% accurate (Salmeron et al., 2003; Wright et 
al., 2000).  In Australia, women would not typically be offered the choice of a 




The causal link between HPV infection and cervical cancer has led to 
development of HPV vaccines to prevent an initial HPV infection. The first 
vaccine to receive marketing approval ad government funding in Australia 
was Gardasil, which targets HPV types 16 and 18 which together cause 70% 
of cervical cancer and HPV types 6 and 11 which cause an estimated 90% of 
cases of genital warts. Being vaccinated does not exempt women from 
screening because the vaccine does not protect against other high-risk strains 
of HPV or eliminate existing exposure to HPV. The vaccine is therefore most 
effective when received prior to sexual debut.  
 
3. Discrete Choice Experiments 
While DCEs have previously been used in a policy evaluation context, a 
novelty of this study is a methodological one demonstrating the use of 
repeated DCEs conducted before and after a policy intervention. 
A DCE is one stated-preference (SP) method of producing behavioural data 
that asks its respondents (subjects) for their preferred choice, as opposed to 
observing their actual decisions in real market situations (which fits a type of 
revealed-preference (RP) data). The behavioural foundation of SP methods is 
Lancastrian consumer theory, which proposes a decomposition of utility 
derived from the consumption of a product into the utilities derived from its 
attributes. Hence, in a DCE, the product of interest is described by its 
attributes and their associated levels, which jointly set a scenario. Studies 
have found that although stated choices are made in a hypothetical setting, in 
which there is no real consequence of making the choice, one goes through a 
similar decision making process as in the real market setting (Louviere et al., 




The DCEs in this study contain the screening determinants and test options. 
The first DCE (DCE1) was developed by Fiebig et al. (2009) in 2004 (pre-
interventions) to quantify the role of these screening factors in women’s 
screening decisions. In June 2007, after both government interventions were 
introduced, the experiment was rerun (DCE2). The content of the DCEs is 
described below.  
 
A scenario is described by a combination of alternative-specific attributes, 
which reflect the characteristics of a given test, and common or context 
attributes, which aim to capture the environment in which the screening 
decision has to be made. Common attributes are fixed across alternatives. 
Table 1 summarises all the attributes and their levels.  
 
[Insert Table 1 about here] 
 
The combination of common and alternative-specific attributes produces over 
16 million (44 x 24 x 43 x 2) possible scenarios. Experimental design techniques 
are as described in Burgess and Street (2004a, 2004b) and Fiebig et al. (2009) 
are used to reduce the potential scenarios to a manageable fraction, while 
retaining the ability to identify the utility weight of each attribute 
independently of each other. The process leads to 512 scenarios, comprising 
32 treatment combinations for the common attributes and 16 treatment 
combinations for the alternative-specific attributes. The scenarios are then 
blocked into 16 versions of 32, with each version including all 32 treatment 
combinations for the common attributes. A respondent is randomly allocated 
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to one of these 16 versions. After considering a scenario, the respondents 
have to choose whether to have a standard Pap test (P) or a liquid-based Pap 
test (L), and whether to have an additional HPV test with the selected Pap test 
(PH, LH). The No test (NT) option is also available.  
 
The surveys also collect personal information on the respondents, such as age 
and income. Also included in DCE2 are four additional questions regarding 
their awareness about the HPV vaccine and test and personal experience with 
any of these measures.  
 
4. Methodology  
4.1. The econometric model 
The foundation of our modelling is random utility theory. Thus, if 
(1) isjisjisj VU ε+= , 
where  isjU  represents the indirect utility function of respondent i  in scenario 
s
 for alternative j , isjV  being the deterministic component of the utility and 
isjε  capturing all other factors affecting utility that are not included in, then 
the respondent i  will choose j over l if: 
(2)  islislisjisj VV εε +>+ ,    jl ≠∀  (l, =j P, L, PH, LH, NT). 
The presence of the random component ε  in (2) makes it a probabilistic 
statement. The probability that the alternative j is chosen over the other 
possible alternatives therefore can be written as: 
(3) )Pr( jlVV isjislislisj ≠∀−>− εε . 
 
For the deterministic component, let 
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(4) δβ '' ~~ iisjisj zxV += , 
where β~  and δ  are vectors of parameters to be estimated, measuring the 
utility weights of attributes isjx~  on screening choice and the influence of 
socio-demographics iz  on choice, respectively. Generally, the linear-in-
parameters specification is assumed by discrete choice models. To increase 
flexibility, attributes with multiple levels have been represented by 
categorical variables that allow for non-linear relationships between them and 
utility. The different levels of screening attributes are effects-coded, whilst 
the different categories of socio-demographic variables are represented by a 
set of dummy variables. Effects-coding the attributes separates out their 
effects from the effects of the omitted categories of the socio-demographic 
variables on screening choice. For each attribute, the parameter for the 
reference group is internalised in the parameters of the included levels, and is 
given by the negative of their sum (see Bech and Gyrd-Hansen, 2005 for 
further arguments for effects-coding). 
 
By assuming a probability distribution for )( isjisl εε − , we can estimate the 
deterministic component of the utility. Given the panel nature of the data, we 
estimate a mixed logit (MXL) model which also allows dependence between 
alternatives. Let us rewrite (4) so as to separate out the alternative-specific 
constants (ASCs) from isjx~  and denote the remaining vector of attributes as 
isjx . The model is now: 
(5)  δβααααα '' iisjiNTisjiLHisjiPHisjiLisjiPisjisj zxdNTdLHdPHdLdPV ++++++= , 
where dP, dL, dPH, dLH and dNT are dummy variables for standard Pap, 
liquid-based Pap, joint standard Pap and HPV test, joint liquid-based Pap and 
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(6)  ijjij ωαα += ,  ~ijω ),0( Ωiid , 
where jα  represents its mean and ijω  denotes a random component that 
represents a deviation from the mean. A significant deviation around the 
mean would indicate the presence of inherent (individual-specific) taste 
heterogeneity in the sample population.  The resulting composite error term 
consists of two parts, isjε  that is iid (identically and independently distributed) 
and ijω  that would follow a yet-to-be specified distribution and induce 
heteroskedasticity and correlation over alternatives. Notice that ijω  varies 
over respondents, but is fixed over repeated scenarios faced by a respondent, 
thereby inducing serial correlation across scenarios.  
 
The assumption of additive error term implies that the main source of 
heterogeneity is inherent taste heterogeneity among women. Some variations 
however may be related to a particular attribute, and the error component 
model does not capture this source of heterogeneities. Extending the model to 
also allow for heterogeneous preferences may improve the fit and explanatory 
power of the model, but the size of the resulting model can be overwhelming, 
as there are quite a number of attributes to be considered as random. The main 
source of heterogeneity could also be scale heterogeneity, instead of inherent 
taste heterogeneity, or a combination of inherent taste and scale 
heterogeneity. The application of a more flexible model, such as the 
generalized multinomial logit model (GMNL) proposed by Fiebig et al. 
(2010) to allow for alternative sources of heterogeneities is left for future 
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study. However, as we will see later, our results suggest that the role of taste 
heterogeneity is dominant.  
 
The normal distribution is used for (6) reflecting that there are people who 
tend to choose a given alternative, and there are others who tend not to prefer 
it. The location of the mean will suggest the prevalence of each kind of 
preferences.  
 
Under the normality assumption, the choice probability in the MXL model is 
a mixture of logits with a multivariate normal mixing distribution. 
Conditional on the random parameters, the probability will follow the 
standard logit specification. However, as respondent’s taste is unobserved, the 
unconditional probability is an integral of the conditional probabilities over 
all possible values of the random parameters, weighted by its probability 
density function. This problem has no closed-form solution and is 































where j, l = P, L, PH, LH, r indexes a particular draw and R is the total 
number of draws. As only differences in utilities matter, the no test alternative 
is chosen as the base with an associated utility of zero.  
 
The mean of these simulated probabilities is then taken to the objective 
function to be maximised by Maximum Likelihood. Halton draws are used in 
the simulation instead of random draws to increase the accuracy of 
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estimation. The random intercepts are allowed to be freely correlated with 





























4.2. Treated and control groups  
To identify the effects of the interventions on screening choice and utility 
weights, we need definitions of the treated group, which has been affected by 
the interventions, and the control group. The DCE1 respondents are a clear 
control group, as this survey was collected pre-interventions. However, 
relying on time variation has the limitation of not knowing the extent of each 
woman’s exposure to the interventions; there is no information in the survey, 
for example, about women’s awareness of the screening promotion 
advertisement. In the extreme case, it is possible that all women in DCE2 are 
unaware of both the screening promotion materials and the vaccination 
program, making them fit the definition of a control group. To deal with this 
problem, several other definitions for the treated and control groups are 
proposed. There are 4 cases in total, which are summarised in Table 2.  
 
[Insert Table 2 about here] 
 
Essentially the other comparison samples (Cases 2–4) are split-samples of 
DCE2. Case 2 uses the extra questions about HPV awareness and define 
respondents who have ever heard of, or experienced the HPV test or vaccine 
prior to the experiment as treated. Meanwhile, Case 3 and 4 make use of the 
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randomisation exercise in DCE2, which allocated respondents into two 
groups, but only one of the two groups was treated. The treatment was 
information on HPV facts and HPV-based measures. To ensure that women in 
the treated group have just the amount of information set by the experiment, 
those with prior knowledge of HPV are excluded. Finally, women who have 
prior knowledge of HPV and got randomly allocated into the treatment group 
can also form a treated sample.  
 
The MXL model is estimated independently for treated and control samples. 
By doing so, we can test if samples have different scales (the overall extent of 
unobserved heterogeneity). In discrete choice models, the scale factor is 
confounded by the utility parameters. However, the identification of the scale 
factor is desirable, as a larger scale implies a lower variance of the 
unobservables, which may result from increased awareness. Furthermore, 
from a policy point of view, different policy strategies are appropriate if 
women have the same response patterns with respect to choice attributes, but 
one group of women is more variable in its behaviour than others, from those 
that are appropriate in the situation in which the underlying behavioural 
parameters have genuinely changed after the interventions.  
 
5. Results 
5.1. Screening choice responses 
Respondents for the survey were a stratified random sample of women living 
in New South Wales aged 18-69 who had previously had a Pap test. Each 
experiment involves a different sample. DCE1 consists of 167 previously-
screened women. As each respondent provided responses to 32 scenarios, 
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there are 5,344 respondent-scenarios. In DCE2, there are 154 previously-
screened women to make a total of 4,928 respondent-scenarios. However, one 
respondent is dropped because she is over 70 years of age and cervical 
screening is no longer recommended for women in this age group and 25 
respondent-scenarios are dropped due to multiple responses in a given 
scenario. Compared to women in DCE1, women in DCE2 tend to be younger, 
more educated, born overseas and have higher incomes (Johar et al., 2009). 
We control for these differences in the estimation. 
 
The distribution of responses is reported in Table 3. In all cases, the shares of 
women who chose no test are shown to be higher in the treated than in the 
control samples. The difference is statistically significant in Case 1 and 4, 
which both involve comparison against pre-treatment period. This pattern is 
inconsistent with the prior expectation that awareness would motivate 
screening participation. Investigating further, this overall increase in non 
participation is found to be driven by young women’s choices. For instance, 
in DCE1, the share of women under 20 who chose no test was 26%, while in 
DCE2, this group of women has 55% non-participation rate. This age-specific 
phenomenon thus hints that the drop in participation rate is related to the 
parallel vaccination program, which is targeted to these young women. For 
instance, they may falsely believe that vaccination and screening are 
alternative strategies to prevent cervical cancer, and that getting vaccinated 
can substitute for screening. If so, the vaccination program actually 
counteracts some of the effect of the screening promotion campaign, rather 
than working together with it to achieve the common goal of cervical cancer 
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prevention. Meanwhile, the share of a given test alternative is on average 
stable between a pair of comparison samples.   
  
[Insert Table 3 about here] 
 
5.2. Preference and attribute values 
The MXL models are estimated using the routine by Hole (2007) in STATA. 
A way to measure the gain from estimating MXL from iid-based models is to 
compare their log-likelihood values. It is found that the improvements are 
quite substantial, measuring 28 to 30% (22 to 28%) of the log-likelihood 
values of the conditional logit model without (with) alternative-specific 
constants across samples and 14 to 26% of the log-likelihood values of 
multinomial logit.  
 
Table 4 reports the results for Case 1. First considering the random intercepts, 
in the treated sample (DCE2), all the mean intercepts are negative and 
statistically significant, predicting that in given a scenario, the reference 
women in the sample (i.e., young women with low education and income, 
born in Australia, and who were never smokers) would tend to choose not to 
be tested. On the other hand, the reference women in the control sample 
(DCE1) are indifferent between no test and a standard Pap test. The location 
of each of the mean intercepts in DCE2 is further to the left from its 
counterpart in DCE1, suggesting results that are consistent with the raw data 
discussed earlier, that the joint interventions have generated negative 
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preferences towards testing in general.1 However, the interventions seem to 
reduce the extent of heterogeneity surrounding a given test alternative. The 
standard deviations around the means are all large and significant, but are 
slightly smaller in magnitude in DCE2. Moreover, these deviations are not 
always larger than their respective means, which is the case in DCE1. 
Meanwhile, both samples exhibit significant correlation in pairwise 
alternatives, except between P and LH. This exception is sensible, as serial 
correlation is personal, and women who have a taste for technology would be 
most likely to choose a liquid-based Pap test over the standard Pap test. 
 
[Insert Table 4 about here] 
 
Next, to compare attribute parameters from the two samples, Figure 1A 
plots the set of estimates from DCE2 against those obtained from DCE1. In 
non-linear models, this device isolates differences in scales (overall 
variance) from genuine differences in utility weights; coefficient estimates 
from different samples are not directly comparable due to confounded 
scales, which can be sample-specific. Scaling phenomenon implies a 
systematic difference between the parameter estimates from different 
samples, with estimates from the sample exhibiting a larger scale being 
scaled down. On a scatter plot of treated sample against control sample, 
these estimates will have a linear relationship with slope steeper than a 45-
                                                 
1
 One can find the probability of getting a value less than 0 of a normally distributed 
random variable with mean and standard deviation equal to the MXL estimates for each 
alternative. For instance, for a standard Pap test the probability of getting a value less than 0 
of a normally distributed random variable with mean 1.5 and standard deviation 2.5 is 0.73 
in DCE2.  
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degrees line. Meanwhile, points above the 45-degree line indicate larger 
estimates in the treated sample.   
 
[Insert Figure 1 about here] 
 
For the attributes, the plot shows that the differences in utility weights are 
largely systematic. While there is no obvious reason why women should 
change their valuations of screening attributes following the interventions, 
one can imagine that awareness of screening importance reduces the weights 
on costs and/or increases the weights on accuracy. The results however 
suggest that screening participation has always been highly influenced by 
provider characteristics and recommendation, and costs and test accuracy 
received unchanging weights.  
 
The different coding system for attributes and the socio-demographic 
variables turns out to be important, as the effects of socio-demographics, 
unlike the attributes’ weights, vary with samples. Although most of them are 
not statistically significant, the reversing sign of the coefficients on education 
and smoking variables to positive is noteworthy. That is, in DCE2, higher 
education increases the propensity to test, and smokers and ex-smokers are 
more likely to test than non-smokers. The changing behaviour related to 
smoking habits in particular is a positive outcome from the perspective of 
women’s health, as smoking increases the risk of developing cervical cancer. 




Figure 1B-D summarises the results from other cases. The underlying results 
can be found in Johar et al., (2009).2 As in Case 1, the relationship between 
attributes’ weights in the other comparison samples is largely one-to-one. On 
the other hand, inherent taste for screening and socio-demographics’ effects 
are sample-specific; due to the dummy-coding of the socio-demographic 
variables, they are linked with the random intercepts.  
 
Comparing the inherent preference for screening between women with prior 
knowledge of HPV (Prior sample) and those who were unaware of it (No 
Prior sample), the reference women in the Prior sample are found to be much 
less averse towards screening. In Figure 1B, this result is depicted by all the 
mean intercepts of the tests (ASCs) located above the 45-degrees line. 
However among women in the No Prior sample, those who have smoking 
history and/or have high income and education are much more likely to 
participate in screening. Meanwhile, from the comparison samples based on 
randomisation, women in the Informed sample tend to be more averse 
towards testing than those in the Uninformed sample. In Figure 1C, in 
contrast to the earlier result, all the test intercepts lie below the 45-degrees 
line. A similar pattern is portrayed in Figure 1D, in comparing women in 
DCE1 and women in the Prior, Informed sample. These last two results are 
somewhat puzzling given that the treatment in the randomisation exercise was 
information on HPV facts. A possible explanation has to do with women’s 
changing assessment of their susceptibility to developing the cancer. For 
instance, the treatment mentioned the causal link of HPV infection to cervical 
cancer and the fact that in most cases, the HPV infection will clear by itself. It 
                                                 
2
 Also available as supplementary online material to this article. 
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could be the case that women who had ever heard of HPV previously thought 
cervical cancer is caused by some other factors, which might have been more 
acute. If so, this new information may cause them to revise their risk of 
contracting the cancer downwards. Some women might have encountered the 
HPV test or vaccine, but even test participants could be unaware of HPV 
facts.  
 
5.3. Eligibility for free Gardasil 
Whether it is the parallel vaccination program in particular that creates the 
aversion towards testing can be checked by removing young women (under 
30 years old), who are eligible for the vaccination program, from the DCE2 
sample. This restriction reduces the sample by nearly half.  
 
Table 5 shows that now all test means are statistically indifferent from zero, 
suggesting that the targeted vaccination program that occurs at the same time 
as the screening promotion is a part of the story. Meanwhile the results 
regarding the screening attributes are largely consistent with those obtained 
from the unrestricted sample; the correlation coefficient between them is 0.98. 
As additional information on the test preference of older women, the 
restriction was also imposed on DCE1. We find that all test mean intercepts 
are negative and significant. Variations around the means are substantial in 
any case, but that for the joint liquid-based Pap and HPV test alternative is 
considerably smaller in size in the DCE2 sample.  
 




To sum up, despite the screening promotion effort, the majority of women 
(still) prefer not to be screened. Spatial comparisons suggest that this is due to 
a reduction in the taste for screening related to HPV events. Meanwhile, the 
values of screening attributes to a typical woman and the overall scale, which 
one may interpret as measuring the extent of uncertainty surrounding 
screening decision-making in general, appear to be independent of any 
intervention. The policy implication following these results is therefore for 
future screening promotion effort to integrate the HPV innovations. In 
particular, the relationship between cervical cancer, screening, HPV facts, and 
HPV-based measures must be communicated in an orderly fashion to avoid 
confusion and prevent women from making false self-assessments of their 
risk of developing the cancer. Better delivery of information may also reduce 
the uncertainties surrounding the screening decision.  
 
5.4. Policy simulations 
Given the significant role of providers in women’s screening decisions, 
stimulating their involvements seems to be a plausible strategy to boost 
screening rates. Using the attributes related to the GP in the experiment, 
simulation is used to forecast the impact of this strategy. As alternative 
strategies, let us consider a price reduction, which is the common policy 
instrument to increase demand and an investment in Research and 
Development (R&D) that produces a more accurate Pap test. Currently, the 
standard Pap test is covered by Medicare, but the newer tests would involve 




Consider the case for a representative woman who is on-time for screening 
(the last test occurred within 2 years). To reflect reality, we specify 
recommended screening interval at 2 years. Other attributes are selected so 
that the predicted screening rate in DCE1 for 20-69 years old is consistent 
with the actual two-year participation rate for these groups of women 
according to the Australian Institute of Health and Welfare’s (AIHW) report, 
which is 58% in 2003-2004 (AIHW, 2008). The corresponding market share 
for 2007 onwards is not (yet) available. This alignment requires the GP to be 
specified as male and as the regular GP of the women. The HPV test costs 
$50, and is not recommended. With regards to test accuracy, we set the false 
positive and negative rates at 1% and a 20%, respectively 
 
The ‘price effect’ ( 1E ), ‘provider effect’ ( 2E ) and ‘R&D effect’ ( 3E ) to 








































where N  is the sample size, and iNTP  is the individual average of the 
probability of no test (NT) alternative from 100 draws, drawn from their 
estimated distributions. The parameters are given by the MXL estimates. The 
superscript H  ( L ) denotes the case in which screening was recommended 
without the test type specified and the liquid-based Pap test costs an 
additional $40 ($10), superscript P  ( NR ) denotes the case in which the GP 
recommended the standard Pap test (not recommending testing), and 
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superscript A  denotes the case in which the accuracy of the standard Pap 
increases to a 0.1% false positive rate and a 5% false negative rate. The R&D 
effect is found using the probability of no test under the low price case, LNTP , 
as the reference point. Within-sample variations are achieved by the random 
draws as well as variations in socio-demographics characteristics.  
 
Table 6 reports the results for (9) – (11). For the extent of the policy change 
considered, all of the three policies have considerable effects on the screening 
rate. The price subsidisation can reduce the non-participation rate by around 
20% in most samples. Meanwhile, by encouraging health providers to take a 
more active role in screening promotion (perhaps, in women’s visits for other 
purposes), the non-participation rate can be reduced by 40 to 50%. A large 
provider effect is indeed not impractical (Myers et al., 2008). R&D spending 
on technology research has a similar-size effect to the provider effect, but 
arguably, the R&D returns take longer. For an immediate impact, the 
government therefore may consider the price strategy, although a generous 
subsidy (in the above case 75% of the costs) may be needed for large effects, 
and/or extending incentives for opportunistic screening (e.g., amending the 
current Practice Improvement Program (PIP)). For the longer run effect, 
resources can be allocated to R&D that improves test accuracy. 
 
[Insert Table 6 about here] 
 
6. Conclusion 
This study has analysed changes in women’s attitudes towards cervical 
screening following the latest (2007) screening promotion campaign and a 
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parallel vaccination program providing HPV vaccine, Gardasil, in Australia. 
The successes of previous screening promotion campaigns and other 
preventive health campaigns (e.g., the SunSmart program in Victoria state, 
Australia, which aims to lower skin cancer rate) led to the expectation that the 
promotion campaign would substantially increase the cervical screening rate. 
However, it is found that the proportion of women willing to be screened is 
generally lower after the joint interventions. This trend is unexpected, but at 
least in Australia, there is no precedent for concurrently running a screening 
promotion campaign and a vaccination program. 
  
The reduction in the participation rate appears to be associated with HPV 
events. First, the reduction in willingness-to-screen is particularly marked 
among young women, who can obtain Gardasil for free under the vaccination 
program. Meanwhile, there is little evidence that given individual 
characteristics, the older women are averse towards testing. These results 
therefore suggest that while screening and vaccination are both preventive 
means for cervical cancer, the effectiveness of the screening promotion effort 
need not be enhanced by the vaccination program. Second, women who were 
newly informed about HPV facts tend to have a stronger aversion towards test 
alternatives than otherwise similar uninformed women. Their willingness to 
be screened may fall as they misinterpreted HPV facts and re-adjusted their 
risk of developing the cancer downwards. If so, it is clear that women require 
clarification about the position of screening in the face of the innovations 




Through a simulation exercise, several potential strategies to increase future 
screening rates were evaluated, and the result suggests that encouraging a 
more active role of health providers is the most effective strategy among 
those considered to achieve this goal, capable of reducing the non-
participation rate by close to one half. Meanwhile, R&D spending on 
technology that improves test accuracy can be justified on the basis of its 
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Last cervical screening appointment 1 year ago; 2 years ago; 3 years ago; 5 years ago 
The recommended screening interval 1 year; 2 years; 3 years; 5 years 
Contact with GP  Regular GP seen for most care; Never seen before  
Sex of GP Female; Male 
Recommendation of GP No test; Standard Pap; Liquid-based Pap; Any Pap test 
Financial incentive to GP No; Yes 
   
Alternative-specific (Pap test) Standard Pap  Liquid-based Pap  
Cost of Pap test $0; $10; $20; $30  
A+$10; A+$20; A+$30; 
A+$40   
False negative rates  1/20; 1/15; 1/10; 1/5  1/100; 1/33; 1/20; 1/10 
False positive rates  1/1000; 1/250; 1/150; 1/100 1/2000; 1/500; 1/150; 1/100 
   
Alternative-specific (HPV test)  No HPV test HPV test 
Cost of HPV test  0 $50; $100; $150; $200 
Recommendation to additional test 0 No test; test 
 
Table 2: Comparison samples 
Case Treated Control 
1. DCE2  DCE1  
2. DCE2 with prior knowledge (Prior) DCE2 without prior knowledge (No prior) 
3. 
 
DCE2 without prior knowledge, informed  
(Informed) 




DCE2 with prior knowledge, informed  




Table 3: Sample mean of choice responses  
Case No. 1 2 3 4 
Choice/Sample Treated Control Treated Control Treated Control Treated Control 
 DCE2 DCE1 Prior No Prior Informed Uninformed Prior, Informed DCE1 
No test 0.429* 0.373 0.431 0.419 0.432 0.410 0.444* 0.373 
Standard 0.228* 0.296 0.188* 0.271 0.243* 0.292 0.197* 0.296 
Standard, HPV test 0.103 0.095 0.099 0.108 0.106 0.110 0.068* 0.095 
Liquid 0.118 0.118 0.126 0.111 0.148* 0.083 0.126 0.118 
Liquid, HPV test 0.123 0.119 0.157* 0.090 0.073* 0.105 0.165* 0.119 
N 5344 4871 2427 2444 1053 1391 1373 5344 
Note: * indicates difference with control group is statistically significant at 1% level based 
on two-mean sample comparison test. The sample size is the number of respondents * 32 
scenarios. In DCE2, the sample excludes the 70 year old women and multiple responses as 








Table 4: MXL results – Case 1 
  DCE1 DCE2   DCE1 DCE2 
  Coeff. p Coeff. p  Coeff. p Coeff. p 
Socio-demo 
    
Alt-spec: Pap test 
  
Age 0.005 0.620 0.004 0.693 Cost: A+$20   0.318 0.000 0.268 0.000 
Trade certificates -0.222 0.618 0.312 0.478 Cost: A+$30   0.060 0.189 0.036 0.444 
Some uni -0.525 0.173 0.889 0.139 Cost: A+$40  -0.418 0.000 -0.449 0.000 
Completed uni 0.160 0.658 0.139 0.755 Cost: A+$10  0.041  0.146  
Inc $50- $80,000 0.342 0.343 -0.594 0.183 FP: 1/250, 1/500  0.021 0.652 0.113 0.015 
Inc >$80,000 0.243 0.511 0.085 0.850 FP: 1/150, 1/150  -0.029 0.524 -0.059 0.208 
Inc missing -0.972 0.036 0.671 0.586 FP: 1/100, 1/100 -0.205 0.000 -0.321 0.000 
Not Australian-born 0.075 0.853 0.284 0.425 FP: 1/1000, 1/2000 0.214  0.268  
Current smoker -0.452 0.182 0.598 0.164 FN: 1/15, 1/33  0.024 0.590 0.041 0.379 
Ex-smoker -0.114 0.762 1.094 0.017 FN: 1/10, 1/20  0.028 0.533 0.055 0.239 
Common  
    FN: 1/5, 1/10 -0.239 0.000 -0.296 0.000 
Interval: 1 year 0.715 0.000 0.811 0.000 FN: 1/20, 1/100   0.186  0.201  
Interval: 3 years -0.127 0.062 -0.137 0.061 Alt-spec: HPV test     
Interval: 5 years -0.858 0.000 -1.021 0.000 Rec: HPV test  0.571 0.000 0.517 0.000 
Interval: 2 years 0.270  0.347  Rec: no HPV test -0.571  -0.517  
Last screen: 2 years  -0.061 0.374 -0.205 0.004 HPV cost: $100 -0.028 0.719 0.005 0.955 
Last screen: 3 years  0.295 0.000 0.406 0.000 HPV cost: $150 -0.411 0.000 -0.540 0.000 
Last screen: 5 years  0.951 0.000 1.102 0.000 HPV cost: $200 -0.784 0.000 -0.694 0.000 
Last screen: 1 year  -1.185  -1.303  HPV cost: $50 1.223  1.229  
GP: new -0.522 0.000 -0.605 0.000 Intercepts (ASCs)     
GP: seen before 0.522  0.605  P -0.445 0.414 -1.500 0.007 
GP: male -0.469 0.000 -0.705 0.000 Std. dev 2.671 0.000 2.489 0.000 
GP: female 0.469  0.705  L -1.331 0.014 -2.307 0.000 
Rec: standard 0.540 0.000 0.492 0.000 Std. dev 2.481 0.000 2.236 0.000 
Rec: liquid  0.067 0.318 0.182 0.010 PH -2.299 0.000 -2.898 0.000 
Rec: any Pap 0.365 0.000 0.337 0.000 Std. dev 2.943 0.000 2.786 0.000 
Rec: no test -0.972  -1.013  LH -2.541 0.000 -3.127 0.000 
GP: get finc incentive -0.049 0.215 0.059 0.153 Std. dev 3.975 0.000 2.940 0.000 
GP: no finc incentive 0.049  -0.059  Correlation*     
     P, L 0.498 0.000 0.657 0.000 
     P, PH 0.507 0.000 0.504 0.000 
     P, LH 0.057 0.115 -0.012 0.844 
     L, PH 0.558 0.000 0.387 0.000 
     L, LH 0.765 0.000 0.449 0.000 
     PH, LH 0.675 0.000 0.715 0.000 
          
     N 26,720  24,355  
     Log L -5,158   -4,681   
Note: Reported under Coeff column are MXL coefficients, and under p column is the 
probability value that the respective coefficient is equal to zero. Coefficients without 
probability values are coefficients of the reference group. ‘Rec’ stands for GP’s 
recommendation. For standard Pap, the cost levels are $0, $10, $20 and $30, and the 
costs of liquid-based test add to these cost. For false positive (FP) and false negative 
(FN) rates, the first figure is for standard Pap and the second is for liquid-based test. * p-







Table 5: MXL results: a sample of women over 30 years old in DCE2  
 
Restricted DCE1 Restricted DCE2 
 
Restricted DCE1 Restricted DCE2 
  
Coeff. p Coeff. p 
 
Coeff. p Coeff. p 
Socio-demographics   
  
Alt-spec: Pap test     
Age 0.034 0.035 -0.040 0.036 Cost: A+$20 0.375 0.000 0.308 0.000 
Trade certificates 0.214 0.682 0.249 0.606 Cost: A+$30  0.074 0.166 -0.053 0.428 
Some university 0.503 0.249 0.279 0.696 Cost: A+$40 -0.478 0.000 -0.436 0.000 
Completed university 0.599 0.214 0.425 0.410 Cost: A+$10  0.029  0.180  
Inc $50 - $80,000 0.095 0.819 -0.280 0.554 FP: 1/250, 1/500 -0.012 0.826 0.183 0.005 
Inc >$80,000 0.473 0.277 -0.783 0.157 FP: 1/150, 1/150 -0.002 0.971 -0.071 0.288 
Inc missing -1.651 0.001 0.179 0.837 FP: 1/100, 1/100 -0.225 0.000 -0.364 0.000 
Not born in Australia -0.415 0.246 0.487 0.257 FP: 1/1000, 1/2000  0.238  0.251  
Current smoker -0.049 0.927 0.110 0.840 FN: 1/15, 1/33 0.037 0.487 0.059 0.369 
Ex-smoker -0.367 0.339 1.743 0.000 FN: 1/10, 1/20  0.033 0.532 0.038 0.565 
Common      FN: 1/5, 1/10 -0.247 0.000 -0.293 0.000 
Interval: 1 year 0.754 0.000 0.851 0.000 FN: 1/20, 1/100 0.177  0.196  
Interval: 3 years -0.095 0.234 -0.085 0.417 Alt-spec: HPV test     
Interval: 5 years -0.969 0.000 -1.092 0.000 Rec: HPV test 0.527 0.000 0.537 0.000 
Interval: 2 years 0.309  0.326  Rec: no HPV test -0.527  -0.537  
Last screen: 2 years  -0.060 0.449 -0.285 0.005 HPV cost: $100 -0.051 0.581 -0.053 0.664 
Last screen: 3 years  0.308 0.000 0.445 0.000 HPV cost: $150 -0.473 0.000 -0.558 0.000 
Last screen: 5 years  1.038 0.000 1.340 0.000 HPV cost: $200 -0.838 0.000 -0.497 0.000 
Last screen: 1 year  -1.286  -1.501  HPV cost: $50 1.362  1.108  
GP: new -0.568 0.000 -0.702 0.000 Intercepts (ASCs)     
GP: seen before 0.568  0.702  P -1.936 0.079 0.717 0.436 
GP: male -0.414 0.000 -0.734 0.000 Std. dev 2.880 0.000 3.083 0.000 
GP: female 0.414  0.734  L -2.204 0.044 0.314 0.735 
Rec: standard 0.505 0.000 0.436 0.000 Std. dev 2.865 0.000 2.408 0.000 
Rec: liquid-based 0.038 0.633 0.139 0.173 PH -3.674 0.001 -1.025 0.297 
Rec: any Pap 0.354 0.000 0.264 0.009 Std. dev 3.030 0.000 3.389 0.000 
Rec: no test -0.897  -0.838  LH -3.143 0.003 -0.859 0.359 
GP: get finc incentive -0.070 0.127 0.046 0.441 Std. dev 5.118 0.000 3.647 0.000 




















L, LH 0.728 0.000 0.521 0.000 
 
    
PH, LH 0.598 0.000 0.732 0.000 
 
         
 
    N 20,160  12,940 
 
 
    
Log L -3,691  -2,301  
Note: The number of replication for simulated probabilities are R=1000. * p-values based 
on covariance terms. Only 25 percent of DCE1 sample are aged less than 30. The number 
of women in the restricted sample is 81. Results for unrestricted case DCE2 are reported in 









Table 6: Simulation results on the probability of no test 
Sample N 1E  Std. Dev 2E  Std. Dev 3E  Std. Dev 
    [%]  [%]  [%]  
DCE1  167 -0.051 0.006 -0.176 0.062 -0.079 0.011 
    [17.41%]  [43.92%]  [32.60%]  
DCE2 153 -0.076 0.007 -0.196 0.014 -0.118 0.016 
    [19.63%]  [40.24%]  [38.09%]  
95% CI of DCE1 means (-0.067, -0.037) (-0.222, -0.135) (-0.112, -0.054) 
DCE2 Sub-samples 
      
No Prior 77 -0.097 0.014 -0.197 0.023 -0.127 0.030 
    [23.03%]  [38.80%]  [39.36%]  
Prior 76 -0.068 0.009 -0.223 0.025 -0.126 0.026 
    [17.29%]  [43.15%]  [39.06%]  
Uninformed 44 -0.074 0.019 -0.170 0.039 -0.106 0.033 
    [16.65%]  [31.69%]  [28.62%]  
Informed 33 -0.132 0.034 -0.242 0.054 -0.157 0.062 
    [31.87%]  [47.95%]  [55.42%]  
Prior, Informed 43 -0.074 0.017 -0.181 0.038 -0.100 0.033 
    [18.09%]  [36.92%]  [29.86%]  
95% CI of No prior means (-0.012, -0.055) (-0.234, -0.122) (-0.173, -0.055) 
95% CI of Prior means (-0.085, -0.035) (-0.276, -0.129) (-0.178, -0.053) 
Note: 95% CI denotes 95% confidence interval:
x
x σ2± . 1E , 2E  and 3E reports the average 
price effect, provider effect and R&D effect, respectively, in terms of change in 
probability of no test. In square brackets are the effects as a proportion change from the 
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